Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non Small Cell Lung
- Registration Number
- NCT00191256
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 77
Inclusion Criteria
- Histologically or cytologically confirmed non small cell lung cancer
- No prior chemotherapy or radiation for non small cell lung cancer
- No prior malignancy
Exclusion Criteria
- Pregnancy or breastfeeding
- Serious concomitant disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Pathological complete response rate, in previously untreated patients with clinical Stage I and II non-small cell lung cancer (NSCLC).
- Secondary Outcome Measures
Name Time Method Response rate, disease free survival,toxicities including pulmonary toxicity, operative mortality, and quality of life.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie gemcitabine's efficacy in preoperative NSCLC treatment?
How does gemcitabine/carboplatin compare to gemcitabine/paclitaxel in preoperative NSCLC outcomes?
Which biomarkers correlate with pathological response to gemcitabine-based preoperative chemotherapy in NSCLC?
What are the key adverse events associated with gemcitabine-based preoperative regimens in early-stage NSCLC?
How do gemcitabine-containing regimens compare to other preoperative chemotherapies for stage I/II non small cell lung cancer?
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇺🇸Chapel Hill, North Carolina, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.🇺🇸Chapel Hill, North Carolina, United States